Nanobiotix, a late-stage French developer of nanoparticle drugs that improve cancer radiotherapy, raised $99 million by offering 7.3 million ADS equivalents at $13.50, the low end of the range of $13.50 to $14.50. The company offered 0.8 million more ADS equivalents than anticipated. It originally planned to offer its securities at the as-converted close of its shares on the Euronext Paris (NANO), before setting the range to $13.50 to $14.50 on Wednesday. At pricing, the company commands a fully diluted market value of $502 million.
Nanobiotix plans to list on the Nasdaq under the symbol NBTX. Jefferies, Evercore ISI and UBS Investment Bank acted as lead managers on the deal.
